Anavex Life Sciences Corp (AVXL)

[Investor2014]

The main issue possible with the AD P2b/3 trial results is a combination of too little response to A2-73 compared to placebo for sufficiently stat sig outcome and/or insufficient clinically meaningful outcomes even if stat sig.

Anavex may or may not plan to be at CTAD, we don't know although it seems just the right event and timing. Unlikely that TLD cannot be available in time for December. So then:

1) Anavex may not know the outcome just yet, or 2) they know TLR and want more time dig deeper, 3) they will release TLR when ready independently of any CTAD appearance, 4) They will present when ready with more subgroup analysis highlighting encouraging signals to drive the design of a new P3 Precision Medicine trial that Anavex may or may not want to present at CTAD.

I suppose a partnership deal could be horizon either because 1) the TLR is a slam dunk and commercial partnership is required for rapid global penetration, 2) great signal with partner offering to share in development costs and efforts.

Imo more likely Anavex would want to carry on development independently. So in conclusion partnership likely only if slam dunk P2b/3 AD outcome.